Sofpironium bromide

Last updated

Sofpironium bromide
Sofpironium bromide.svg
Clinical data
Trade names Ecclock, others
Other namesBBI-4000, BBI 4000
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Topical
Drug class Anticholinergic
ATC code
  • None
Legal status
Legal status
Identifiers
  • [(3R)-1-(2-Ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C22H32BrNO5
Molar mass 470.404 g·mol−1
3D model (JSmol)
  • CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
  • InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
  • Key:FIAFMTCUJCWADZ-JOFREBOKSA-M

Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). [1] Sofpironium bromide is an anticholinergic agent that is applied to the skin. [1]

Contents

It was approved for medical use in Japan in 2020, [2] and in the United States in June 2024. [1] [3] [4] [5]

Medical uses

Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis. [1]

Mechanism of action

The pharmacodynamics of sofpironium bromide are unknown. [1]

Society and culture

It was approved for medical use in Japan in November 2020, [6] and in the United States in June 2024. [1] [7]

Brand names

Sofpironium bromide is the international nonproprietary name. [8]

It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.

References

  1. 1 2 3 4 5 6 7 "Sofdra- sofpironium bromide gel". DailyMed. 26 August 2024. Retrieved 2 September 2024.
  2. ↑ Paik J (December 2020). "Sofpironium Bromide: First Approval". Drugs. 80 (18): 1981–1986. doi:10.1007/s40265-020-01438-1. PMID   33236266. S2CID   227155835.
  3. ↑ "Drug Approval Package: Sofdra". U.S. Food and Drug Administration (FDA). 17 July 2024. Retrieved 2 September 2024.
  4. ↑ New Drug Therapy Approvals 2024. U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original (PDF) on 21 January 2025. Retrieved 21 January 2025.
  5. ↑ "FDA Approves Sofdra topical gel" (Press release). Botanix Pharmaceuticals. 20 June 2024. Archived from the original on 20 June 2024. Retrieved 20 June 2024.
  6. ↑ "Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (Ecclock) in Japan by its Development Partner, Kaken Pharmaceutical" (Press release). Brickell Biotech. 18 November 2020. Retrieved 2 September 2024– via GlobeNewswire.
  7. ↑ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  8. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl: 10665/330984 .

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.